Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: liver

A Long Path Forward: Complications of COVID-19 in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  September 24, 2024

Emerging evidence shows COVID-19 infection may have long-term consequences, such as arthritis onset and more.

Filed under:ConditionsEULAR/OtherMeeting Reports Tagged with:APLARAPLAR 2024Asia Pacific League of Associations for Rheumatology (APLAR)COVID-19

Don’t Be Afraid to Engage: Health Technologies for Patients & Rheumatologists

Jason Liebowitz, MD, FACR  |  September 24, 2024

Symptom checkers, telehealth and more—here are insights into the effects new technologies are having on rheumatology.

Filed under:Meeting ReportsPractice SupportTechnology Tagged with:APLARAPLAR 2024appsAsia Pacific League of Associations for Rheumatology (APLAR)Personalized medicineTechnologytelehealthtelemedicine

Plan Ahead: Clinical Tips for Managing Reproductive Health in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  September 24, 2024

Dr. May Ching Soh highlighted practical approaches when caring for pregnant patients with rheumatic disease.

Filed under:ConditionsMeeting Reports Tagged with:APLARAPLAR 2024Asia Pacific League of Associations for Rheumatology (APLAR)pregnancypregnancy complicationspregnant women

Updates in RA-Associated ILD

Keri Losavio  |  September 19, 2024

On Sunday, Nov. 17, at ACR Convergence 2024, three speakers will deliver a presentation on Rheumatoid Arthritis-Associated Interstitial Lung Disease: Advances in Screening, Diagnosis and Patient Phenotyping. This session will have three 20-minute presentations that cover distinct aspects of RA-associated ILD from early identification of ILD through high-resolution computed tomography (HRCT) text mining, to phenotyping…

Filed under:ACR ConvergenceConditionsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

Case Report: Leprosy Masquerading as Relapsing Polychondritis

Rohan Goel, MBBS, MD, Rashmi Roongta, MBBS, MD, DM, Dipendranath Ghosh, MBBS, MD, DM, & Parasar Ghosh, MD, DM  |  September 9, 2024

Autoimmune rheumatic diseases (AIRDs) are known for their systemic presentations and multi-organ involvement. Numerous infectious diseases, particularly mycobacterial, fungal and indolent bacterial infections endemic to specific geographic regions, present with varied signs and symptoms of multi-system involvement and can mimic AIRDs. Thus, differentiating infection from an AIRD is critical to resolve competing treatment approaches. This…

Filed under:Conditions Tagged with:case reportInfectionleprosymimicsrelapsing polychondritis

ACR Offers Resources & Personalized Help for Practice Management Questions

From the College  |  August 19, 2024

ACR staff can help members navigate questions on all areas of practice management.

Filed under:Practice ManagementPractice Support Tagged with:Member benefits

Business of Rheumatology Manual: A Preview of What’s to Come

From the College  |  August 17, 2024

Revisions of the handbook to reflect an evolving healthcare landscape are underway, led by the Committee on Rheumatologic Care, Community Practice Council and Insurance Subcommittee. The first new chapters will be available in fall 2024.

Filed under:Practice ManagementPractice Support Tagged with:Committee on Rheumatologic Care (CORC)

Coagulation Education: Treatment Options for Antiphospholipid Syndrome

Jason Liebowitz, MD, FACR  |  July 31, 2024

Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsVasculitis Tagged with:Antiphospholipid syndromeAPScardiovascularEULAR 2024obstetric APSpregnancypregnancy complicationsthrombotic APS

The Truth About Remote Care

Samantha C. Shapiro, MD  |  July 31, 2024

Long wait times for appointments, the rheumatologist shortage in rural areas—does telehealth solve some aspects of access to care for rheumatology patients? Three experts highlighted the data on remote care, unveiling surprising truths and misconceptions.

Filed under:EULAR/OtherGuidanceMeeting ReportsPractice SupportTechnology Tagged with:EULAR 2024healthcare accesspatient careremote caretelehealth

FDA Approves Sarilumab for pJIA

Michele B. Kaufman, PharmD, BCGP  |  July 29, 2024

The FDA has granted sarilumab its first pediatric indication, approving the agent to treat active, polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63 kgs.

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalpJIApolyarticular juvenile idiopathic arthritis (JIA)sarilumabU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 126
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences